Skip to main content

Welcome New Corporate Partners, April 2023

Please join us in welcoming the following companies new to HBA corporate partnership in 2023:


Editas Medicine
CEO: Gilmore O’Neill
As a clinical-stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. 

Corium, Inc.
President and CEO: Perry Sternberg
Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Corium is headquartered in Boston, MA.